Antiviral research · 2016
Reducing the global burden of HTLV-1 infection: An agenda for research and action.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Willems Luc, Hasegawa Hideki, Accolla Roberto, Bangham Charles, Bazarbachi Ali, Bertazzoni Umberto, Carneiro-Proietti Anna Barbara de Freitas, Cheng Hua, Chieco-Bianchi Luigi, Ciminale Vincenzo, Coelho-Dos-Reis Jordana, Esparza José, Gallo Robert C, Gessain Antoine, Gotuzzo Eduardo, Hall William, Harford Joseph, Hermine Olivier, Jacobson Steven, Macchi Beatrice, Macpherson Calum, Mahieux Renaud, Matsuoka Masao, Murphy Edward, Peloponese Jean-Marie, Simon Viviana, Tagaya Yutaka, Taylor Graham P, Watanabe Toshiki, Yamano Yoshihisa
Аннотация
Even though an estimated 10-20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.